logo
Plus   Neg
Share
Email

Vectura Says GlaxoSmithKline Not To Seek Appeal For Re-hearing In Ongoing Ellipta Litigation

Vectura Group plc (VEC.L) confirmed on Tuesday that GlaxoSmithKline (GSK) has not sought to petition the US Court of Appeals for a re-hearing in our ongoing Ellipta litigation.

Accordingly, the Court of Appeals has issued the Mandate to the United States District Court for the District of Delaware.

Vectura said it now expects GSK to make payment of the current award plus interest by late January 2021. The specific amount of the award will be confirmed in due course.

On November 19, the US Court of Appeals had denied GSK's motions for a retrial on infringement and for a new trial on damages. GSK may petition the US Supreme Court to review the decision. Such a petition would not impact the timing of GSK making payments on the award.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test. AstraZeneca's one batch of Covid vaccine has been suspended by Austrian health authorities following reports of a death and an illness after receiving vaccination, reports said. The issues were reported in the district clinic of Zwettl in Lower Austria province. The Federal Office for Safety in Health Care in the country said the remaining stocks of the affected AstraZeneca/Oxford Covid-19 vaccine DuPont (DD) announced Monday that it has agreed to acquire Laird Performance Materials from with private equity firm Advent International for $2.3 billion. The company will use existing cash balances for the acquisition. The transaction is expected to close in the third quarter of 2021, subject to regulatory...
Follow RTT